INTACT GENOMICS INC

Saint Louis, MO · Biotech · Private

Novel antifungal compounds discovered through heterologous expression of fungal biosynthetic gene clusters in engineered Aspergillus nidulans strains

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · intactgenomics.com

Sector: Biotech
Headquarters: Saint Louis, MO
Total capital: $20.7M

Federal grants: $20.6M; 24 awards · 2015–2024; Rank in peer group#61 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $168K; 3 awards · Agriculture, Health and Human S, Defense; Rank in Biotech#302 of 4373
Granted patents: 1; 1 pending · first 2019; Rank in peer group#186 of 514

Capital timeline

Latest events

Jun 2024Federal grantHealth and Human S · Phase II · Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes$960K
Jul 2023Federal grantHealth and Human S · Phase I · A Platform to Identify Antifungal Compounds with Novel Action Mechanisms$300K
Jul 2023Federal grantHealth and Human S · Phase I · A Platform to Identify Antifungal Compounds with Novel Action Mechanisms$300K
Jun 2023Federal grantHealth and Human S · Phase II · Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes$983K
Jul 2022Federal grantHealth and Human S · Phase II · Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes$1.0M
Jul 2022Federal grantHealth and Human S · Phase II · Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes$2M
Jan 2022Federal grantHealth and Human S · Phase II · Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool$1M

Show 20 earlier federal awards

Feb 2021Federal grantHealth and Human S · Phase II · Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool$1M
Feb 2020Federal grantHealth and Human S · Phase II · Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool$3M
Jan 2020Federal grantHealth and Human S · Phase II · Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool$1M
May 2019Federal grantHealth and Human S · Phase II · A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans$746K
Jan 2019Federal grantHealth and Human S · Phase II · Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool$300K
Jul 2018Federal contractDefense · Igf::ot::igf (use Two In-house Protocols And Cloning Kit To Insert An - 73KB Genome Into A Bac Or Other Cling Vector.$8K
Jul 2018Federal grantHealth and Human S · Phase I · Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes$229K
Jul 2018Federal grantHealth and Human S · Phase I · Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes$229K
Jun 2018Federal grantHealth and Human S · Phase II · A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans$1.5M
May 2018Federal grantHealth and Human S · Phase II · A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans$750K
Jun 2017Federal grantHealth and Human S · Phase II · Activate Silent and Cryptic Intact Fungal SM Gene Clusters through FACs for Novel Antibiotics Discovery$873K
Sep 2016Federal contractHealth and Human S · Igf::ct::igf For Critical Functions$150K
Jul 2016Federal grantHealth and Human S · Phase II · Activate Silent and Cryptic Intact Fungal SM Gene Clusters through FACs for Novel Antibiotics Discovery$1.8M
Jul 2016Federal grantHealth and Human S · Phase II · Activate Silent and Cryptic Intact Fungal SM Gene Clusters through FACs for Novel Antibiotics Discovery$901K
Apr 2016Federal grantHealth and Human S · Phase I · A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans$225K
Mar 2016Federal grantHealth and Human S · Phase I · A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans$225K
Jun 2015Federal contractAgriculture · Igf::ot::igf Bacterial Artificial Chromosome Library$10K
Apr 2015Federal grantHealth and Human S · Phase II · Expanding small molecule functional metagenomics through shuttle BAC expression i$861K
Jan 2015Federal grantHealth and Human S · Phase I · Activate Silent and Cryptic Intact Fungal SM Gene Clusters through FACs for Novel Antibiotics Discovery$211K
Jan 2015Federal grantHealth and Human S · Phase I · Activate Silent and Cryptic Intact Fungal SM Gene Clusters through FACs for Novel Antibiotics Discovery$211K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#61 · top 12%
Granted patents#186 · top 36%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 2

Aug 29, 2019PendingFungal Artificial Chromosomes, Compositions, Methods And Uses ThereforUSPTOApplication 16409586
Jul 2, 2019GrantedFungal Artificial Chromosomes, Compositions, Methods And Uses ThereforUSPTOUS 10,337,019

Tenax TherapeuticsSimilar federal contract value in Biotech · $185K in contracts
CANTATA BIO LLCSimilar federal contract value in Biotech · $182K in contracts
Ambient Biosciences, Inc.Similar federal contract value in Biotech · $180K in contracts
REGIS TECHNOLOGIES INCSimilar federal contract value in Biotech · $160K in contracts
Scale BiosciencesSimilar federal contract value in Biotech · $151K in contracts
AMERICAN GENE TECHNOLOGIES INTERNATIONALSimilar federal contract value in Biotech · $150K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.